drugset / Trial / NCT00547365

Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction

NCT00547365

Phase 1/2 Completed 10 enrolled University of Tennessee
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Antibodies, such as human immune globulin, can block the growth of abnormal cells in different ways. Some block the ability of abnormal cells to grow and spread. Others find abnormal cells and help kill them or carry cell-killing substances to them. Giving human immune globulin may be effective in treating patients with primary amyloidosis that is causing heart dysfunction. PURPOSE: This phase I/II trial is studying the side effects and best dose of human immune globulin and to see how well it works in treating patients with primary amyloidosis that is causing heart dysfunction.

Timeline

Start
2007-10
Primary completion
2011-07
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Human immune globulin Unknown Intravenous

Indications